
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is a well-positioned, financially stable company with a strong potential for growth in the transplant testing market. With their diverse product portfolio, recent strategic acquisitions, and positive industry developments, the company is poised for success in the coming years. Additionally, their close collaboration with CMS and focus on innovation solidify their position as a leader in the precision medicine space, making them a promising investment opportunity.
Bears say
CareDx is facing headwinds due to Medicare limiting coverage for its kidney and heart surveillance tests, which we believe will continue to put pressure on the company's core transplant business. Additionally, their new AlloHeme product, while targeting a potentially large market, has not yet established its reimbursement and price, adding uncertainty to future revenue streams. Finally, competition in the precision medicine space for transplant patients is increasing, and CareDx may struggle to maintain its dominant market share and drive revenue growth.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares